KalVista Pharmaceuticals (NASDAQ:KALV) CEO Benjamin Palleiko Sells 10,940 Shares

Key Points

• KalVista Pharmaceuticals CEO Benjamin Palleiko sold 10,940 shares at an average price of $13.22, totaling $144,626.80, reducing his ownership in the company by 2.75%.
• The company reported a quarterly earnings loss of ($3.69) EPS, significantly missing the consensus estimate of ($0.83) per share.
• Analysts have a consensus rating of "Buy" for KalVista Pharmaceuticals, with the average price target set at $26.29, indicating potential upside for investors.

KalVista Pharmaceuticals, Inc. (NASDAQ:KALV - Get Free Report) CEO Benjamin Palleiko sold 10,940 shares of the stock in a transaction dated Friday, August 22nd. The stock was sold at an average price of $13.22, for a total transaction of $144,626.80. Following the transaction, the chief executive officer owned 386,858 shares of the company's stock, valued at $5,114,262.76. This represents a 2.75% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link.

KalVista Pharmaceuticals Stock Performance

NASDAQ KALV traded down $0.42 during trading hours on Monday, hitting $12.99. The company had a trading volume of 543,269 shares, compared to its average volume of 775,347. The firm has a 50 day simple moving average of $13.40 and a 200 day simple moving average of $12.39. KalVista Pharmaceuticals, Inc. has a 52 week low of $7.30 and a 52 week high of $16.32. The firm has a market capitalization of $653.92 million, a price-to-earnings ratio of -3.52 and a beta of 0.05.

KalVista Pharmaceuticals (NASDAQ:KALV - Get Free Report) last posted its quarterly earnings results on Thursday, July 10th. The specialty pharmaceutical company reported ($3.69) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.83) by ($2.86). During the same period in the previous year, the firm earned ($1.07) earnings per share. On average, research analysts forecast that KalVista Pharmaceuticals, Inc. will post -3.56 earnings per share for the current year.

Hedge Funds Weigh In On KalVista Pharmaceuticals

Several institutional investors have recently bought and sold shares of the company. Aquatic Capital Management LLC acquired a new stake in KalVista Pharmaceuticals in the fourth quarter valued at $44,000. Earned Wealth Advisors LLC acquired a new stake in KalVista Pharmaceuticals in the first quarter valued at $44,000. BNP Paribas Financial Markets grew its holdings in KalVista Pharmaceuticals by 47.0% in the second quarter. BNP Paribas Financial Markets now owns 4,041 shares of the specialty pharmaceutical company's stock valued at $46,000 after purchasing an additional 1,292 shares during the last quarter. GAMMA Investing LLC grew its holdings in KalVista Pharmaceuticals by 567.3% in the first quarter. GAMMA Investing LLC now owns 4,431 shares of the specialty pharmaceutical company's stock valued at $51,000 after purchasing an additional 3,767 shares during the last quarter. Finally, CWM LLC grew its holdings in KalVista Pharmaceuticals by 12,636.1% in the first quarter. CWM LLC now owns 4,585 shares of the specialty pharmaceutical company's stock valued at $53,000 after purchasing an additional 4,549 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages have recently issued reports on KALV. HC Wainwright lifted their price target on KalVista Pharmaceuticals from $20.00 to $27.00 and gave the company a "buy" rating in a report on Tuesday, July 8th. JMP Securities raised their target price on KalVista Pharmaceuticals from $19.00 to $27.00 and gave the stock a "market outperform" rating in a research note on Tuesday, July 8th. Finally, Leerink Partners increased their price objective on KalVista Pharmaceuticals from $18.00 to $20.00 and gave the company an "outperform" rating in a research note on Monday, July 7th. One research analyst has rated the stock with a Strong Buy rating and eight have assigned a Buy rating to the company. According to MarketBeat, the company currently has a consensus rating of "Buy" and an average target price of $26.29.

KalVista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of drug therapies inhibitors for diseases with unmet needs. The company's product candidate is Sebetralstat, a small molecule plasma kallikrein inhibitor targeting the disease of hereditary angioedema (HAE).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.